ALDEI Deinove S.A.

2020 Half-year results: Stronger financial position and research programs moving forward despite the international context

2020 Half-year results: Stronger financial position and research programs moving forward despite the international context
EN
01/10/2020

Underlying

ALDEIDeinove S.A.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Deinove S.A.

 PRESS RELEASE
Free
ALDEI DEINOVE S.A.

Conversion of the receivership proceedings into judicial liquidation p...

Conversion of the receivership proceedings into judicial liquidation proceedings CONVERSION OF THE RECEIVERSHIP PROCEEDINGS INTO JUDICIAL LIQUIDATION PROCEEDINGS DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company, pioneer in the exploration and exploitation of bacterial biodiversity to address the urgent, global challenge of antibiotic resistance, announces that on January 23, 2023, the Montpellier Commercial Court rendered a judgment converting the receivership proceedings, initiated on November 7, 2022, into a judicial liquidation proceedings (“procédure de liquidation jud...

January 24, 2023 1 EN
 PRESS RELEASE
Free
ALDEI DEINOVE S.A.

Conversion de la procédure de redressement judiciaire en liquidation j...

Conversion de la procédure de redressement judiciaire en liquidation judiciaire CONVERSION DE LA PROCEDURE DE REDRESSEMENT JUDICIAIRE EN LIQUIDATION JUDICIAIRE DEINOVE (Euronext Growth Paris : ALDEI), société de biotechnologie française pionnière dans l’exploration et l'exploitation de la biodiversité bactérienne pour relever le défi urgent et planétaire de la résistance aux antimicrobiens, annonce que le Tribunal de Commerce de Montpellier a rendu le 23 janvier 2023 un jugement actant la conversion de la procédure de redressement judiciaire, initiée le 7 novembre 2022, en liquidation jud...

January 24, 2023 1 EN
 PRESS RELEASE
Free
ALDEI DEINOVE S.A.

DEINOVE - Update on the receivership proceedings

DEINOVE - Update on the receivership proceedings DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company, pioneer in the exploration and exploitation of bacterial biodiversity to address the urgent, global challenge of antibiotic resistance, announces that, in the context of the receivership proceedings (“procédure de redressement judiciaire”) opened on November 7, 2022, the Montpellier Commercial Court met on January 13, 2023 to examine the case and reserved its decision until January 23, 2023. The listing of the Company's shares (ISIN: FR0010879056), which has been suspended sin...

January 16, 2023 1 EN
 PRESS RELEASE
Free
ALDEI DEINOVE S.A.

DEINOVE - Point sur la procédure de redressement judiciaire

DEINOVE - Point sur la procédure de redressement judiciaire DEINOVE (Euronext Growth Paris : ALDEI), société de biotechnologie française pionnière dans l’exploration et l'exploitation de la biodiversité bactérienne pour relever le défi urgent et planétaire de la résistance aux antimicrobiens, annonce que, dans le cadre de la procédure de redressement judiciaire ouverte le 7 novembre 2022, le Tribunal de Commerce de Montpellier s'est réuni le 13 janvier 2023 afin d'examiner l’affaire et a mis sa décision en délibéré au 23 janvier 2023. La cotation des actions de la Société (ISIN : FR0010879...

January 16, 2023 1 EN
 PRESS RELEASE
Free
ALDEI DEINOVE S.A.

DEINOVE - Update on the Receivership Proceedings

DEINOVE - Update on the Receivership Proceedings DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company, pioneer in the exploration and exploitation of bacterial biodiversity to address the urgent, global challenge of antibiotic resistance, announces that, in the context of the receivership proceedings (“procédure de redressement judiciaire”) opened on November 7, 2022, the Montpellier Commercial Court has met on December 16, 2022, and postponed the examination of the case to January 13, 2023. The continuation of the observation period (“période d'observation”) was requested by th...

December 16, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch